JP2000505787A - 中皮抗原及びそれを標的化するための方法及びキット - Google Patents

中皮抗原及びそれを標的化するための方法及びキット

Info

Publication number
JP2000505787A
JP2000505787A JP9525355A JP52535597A JP2000505787A JP 2000505787 A JP2000505787 A JP 2000505787A JP 9525355 A JP9525355 A JP 9525355A JP 52535597 A JP52535597 A JP 52535597A JP 2000505787 A JP2000505787 A JP 2000505787A
Authority
JP
Japan
Prior art keywords
mesothelin
polypeptide
cells
molecule
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP9525355A
Other languages
English (en)
Japanese (ja)
Inventor
パスタン，イラ
カイ チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2000505787A publication Critical patent/JP2000505787A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP9525355A 1996-01-05 1997-01-03 中皮抗原及びそれを標的化するための方法及びキット Withdrawn JP2000505787A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1016696P 1996-01-05 1996-01-05
US60/010,166 1996-01-05
PCT/US1997/000224 WO1997025068A2 (en) 1996-01-05 1997-01-03 Mesothelin antigen and methods and kits for targeting it

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007002808A Division JP2007197439A (ja) 1996-01-05 2007-01-10 中皮抗原及びそれを標的化するための方法及びキット

Publications (1)

Publication Number Publication Date
JP2000505787A true JP2000505787A (ja) 2000-05-16

Family

ID=21744267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9525355A Withdrawn JP2000505787A (ja) 1996-01-05 1997-01-03 中皮抗原及びそれを標的化するための方法及びキット
JP2007002808A Pending JP2007197439A (ja) 1996-01-05 2007-01-10 中皮抗原及びそれを標的化するための方法及びキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007002808A Pending JP2007197439A (ja) 1996-01-05 2007-01-10 中皮抗原及びそれを標的化するための方法及びキット

Country Status (9)

Country Link
US (2) US6083502A (enExample)
EP (1) EP0871492B1 (enExample)
JP (2) JP2000505787A (enExample)
AT (1) ATE254931T1 (enExample)
AU (1) AU703769B2 (enExample)
CA (1) CA2241604C (enExample)
DE (1) DE69726404T2 (enExample)
ES (1) ES2212071T3 (enExample)
WO (1) WO1997025068A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504372A (ja) * 2007-11-26 2011-02-10 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 抗メソセリン抗体およびその使用
JP2016026211A (ja) * 2009-10-27 2016-02-12 ユセベ ファルマ ソシエテ アノニム 機能改変するＮａｖ１．７抗体
US10647779B2 (en) 2009-04-29 2020-05-12 Bayer Intellectual Property Gmbh Anti-mesothelin immunoconjugates and uses therefor

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314632B1 (en) * 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
CA2295971C (en) * 1997-07-11 2011-02-08 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Pseudomonas exotoxin a-like chimeric immunogens
US6809184B1 (en) * 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
US7745159B2 (en) 1999-02-26 2010-06-29 Nathalie B Scholler Methods and compositions for diagnosing carcinomas
US6770445B1 (en) * 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
JP4813661B2 (ja) * 1999-02-26 2011-11-09 パシフィック ノースウエスト リサーチ インスティテュート 癌を診断するための方法および組成物
US7081518B1 (en) 1999-05-27 2006-07-25 The United States Of America As Represented By The Department Of Health And Human Services Anti-mesothelin antibodies having high binding affinity
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6987024B1 (en) * 2000-04-10 2006-01-17 Raven Biotechnologies, Inc. Human ovarian mesothelial cells and methods of isolation and uses thereof
AU2002338446A1 (en) * 2001-01-23 2002-11-05 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
US7547759B2 (en) 2001-03-09 2009-06-16 Board Of Regents, The University Of Texas System Induction of tumor immunity by variants of folate binding protein
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
AU2003259109A1 (en) * 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7833775B2 (en) * 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US20040180387A1 (en) * 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
EP1651675A1 (en) * 2003-08-05 2006-05-03 Morphotek, Inc. A variant cell surface molecule associated with cancer
US7399793B2 (en) * 2003-10-31 2008-07-15 Basf Corporation Coating composition curable with ultraviolet radiation
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
EP1714151A4 (en) * 2004-01-21 2009-06-10 Fujirebio America Inc DETECTION OF PEPTIDES RELATED TO MESOTHELIN / MEGAKARYOCYTIC POTENTIAL FACTOR IN PERITONEAL LIQUID FOR THE ASSESSMENT OF THE PERITONEUM AND PERITONEAL CAVE
EP1716168A4 (en) * 2004-01-21 2009-06-24 Fujirebio America Inc DETECTION OF PEPTIDES RELATING TO THE FACTOR FOR THE POTENTIATION OF URINARY MESOTHELIN- / MEGACARYOCYTES FOR THE EVALUATION OF MESOTHELIOMA
US20050232919A1 (en) * 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
AU2006223301B2 (en) * 2005-03-10 2010-11-04 Eisai, Inc. Anti-mesothelin antibodies
US20060239910A1 (en) * 2005-04-22 2006-10-26 Morphotek Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
JP5347135B2 (ja) 2006-03-01 2013-11-20 アドゥロ バイオテック 遺伝子工学操作されたｌｉｓｔｅｒｉａおよびその使用方法
WO2008105814A2 (en) * 2006-08-22 2008-09-04 Los Alamos National Security, Llc Miniturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids
AU2008279584A1 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
AR067543A1 (es) 2007-07-16 2009-10-14 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
CN106432496B (zh) 2007-07-16 2020-02-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
JP2009028871A (ja) 2007-07-30 2009-02-12 Denso Wave Inc ロボット制御装置
HRP20150074T1 (hr) 2007-10-01 2015-03-13 Bristol-Myers Squibb Company Humana antitijela koja se vežu za mezotelin i njihove uporabe
EP2247620B1 (en) 2008-01-31 2016-05-18 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
US8357783B2 (en) * 2008-03-27 2013-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human anti-mesothelin monoclonal antibodies
US8785134B2 (en) * 2008-11-10 2014-07-22 The Mitre Corporation Glycoprotein vesicles and their methods of use
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
RU2012114005A (ru) 2009-09-11 2013-10-20 Те Гавернмент Оф Те Юнайтед Стейтс Оф Америка Эз Репризентед Бай Те Секретари Оф Те Департмент Хелт Энд Хьюман Сервисез Усовершенствованный экзотоксин а pseudomonas со сниженной иммуногенностью
WO2011100455A1 (en) 2010-02-12 2011-08-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of antibody responses to foreign proteins
EP3296321B1 (en) 2010-12-20 2020-07-15 F. Hoffmann-La Roche AG Anti-mesothelin antibodies and immunoconjugates
CN103649333B (zh) 2011-04-20 2017-02-15 梅撒生物科技公司 用于核酸检测和鉴定的集成装置
WO2012154530A1 (en) 2011-05-06 2012-11-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant immunotoxin targeting mesothelin
AR087380A1 (es) * 2011-07-27 2014-03-19 Baylor Res Inst Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas
US9127081B2 (en) 2012-05-10 2015-09-08 Washington University Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
AU2013306076B2 (en) 2012-08-21 2018-01-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
EP2900695B1 (en) 2012-09-27 2018-01-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
WO2014182532A1 (en) 2013-05-07 2014-11-13 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Mesothelin-specific immunocytokine and use thereof
SI3262071T1 (sl) 2014-09-23 2020-07-31 F. Hoffmann-La Roche Ag Način uporabe imunokonjugatov proti CD79b
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016172724A1 (en) 2015-04-24 2016-10-27 Mesa Biotech, Inc. Fluidic test cassette
US9993538B2 (en) 2015-05-29 2018-06-12 Galena Biopharma, Inc. Peptide vaccine therapy for treatment of FRα-expressing tumors
WO2017112741A1 (en) 2015-12-22 2017-06-29 Novartis Ag Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
CN109072195A (zh) 2015-12-30 2018-12-21 诺华股份有限公司 具有增强功效的免疫效应细胞疗法
TWI654302B (zh) 2016-01-19 2019-03-21 輝瑞股份有限公司 癌症疫苗
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
PL3443096T3 (pl) 2016-04-15 2023-06-19 Novartis Ag Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych
EP3463438B1 (en) 2016-05-31 2022-04-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
JP2019527696A (ja) 2016-08-01 2019-10-03 ノバルティス アーゲー プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
GB201616699D0 (en) 2016-09-30 2016-11-16 Mab Designs Ltd Antibodies
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
WO2019094482A1 (en) 2017-11-10 2019-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting tumor antigens
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US20240245670A1 (en) 2018-12-20 2024-07-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US12180296B2 (en) 2019-01-08 2024-12-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting mesothelin for treating solid tumors
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR20220116522A (ko) 2019-12-20 2022-08-23 노파르티스 아게 증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN116134027B (zh) 2020-08-03 2025-01-24 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
WO2025240496A1 (en) 2024-05-14 2025-11-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Natural killer cells expressing a mesothelin-targeted chimeric antigen receptor and interleukin-15 for the treatment of solid tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02504517A (ja) * 1987-08-19 1990-12-20 セントカー・インコーポレーテツド ヒト卵巣ガン腫に会合する抗原
JP2660241B2 (ja) * 1990-10-12 1997-10-08 アメリカ合衆国 モノクロナール抗体
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
JP3328341B2 (ja) * 1991-12-27 2002-09-24 中外製薬株式会社 新規な巨核球増幅因子
JP3490125B2 (ja) * 1992-10-23 2004-01-26 中外製薬株式会社 巨核球増幅因子をコードする遺伝子
IL107366A (en) * 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504372A (ja) * 2007-11-26 2011-02-10 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 抗メソセリン抗体およびその使用
JP2014221064A (ja) * 2007-11-26 2014-11-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 抗メソセリン抗体およびその使用
JP2018102311A (ja) * 2007-11-26 2018-07-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 抗メソセリン抗体およびその使用
US10647779B2 (en) 2009-04-29 2020-05-12 Bayer Intellectual Property Gmbh Anti-mesothelin immunoconjugates and uses therefor
US10781263B2 (en) 2009-04-29 2020-09-22 Bayer Intellectual Property Gmbh Anti-mesothelin immunoconjugates and uses therefor
JP2016026211A (ja) * 2009-10-27 2016-02-12 ユセベ ファルマ ソシエテ アノニム 機能改変するＮａｖ１．７抗体

Also Published As

Publication number Publication date
DE69726404D1 (de) 2004-01-08
ES2212071T3 (es) 2004-07-16
AU703769B2 (en) 1999-04-01
CA2241604C (en) 2010-03-30
CA2241604A1 (en) 1997-07-17
WO1997025068A2 (en) 1997-07-17
US6083502A (en) 2000-07-04
ATE254931T1 (de) 2003-12-15
AU1692797A (en) 1997-08-01
WO1997025068A3 (en) 1997-10-23
EP0871492B1 (en) 2003-11-26
US6153430A (en) 2000-11-28
JP2007197439A (ja) 2007-08-09
EP0871492A2 (en) 1998-10-21
DE69726404T2 (de) 2004-09-09

Similar Documents

Publication Publication Date Title
JP2000505787A (ja) 中皮抗原及びそれを標的化するための方法及びキット
US6689744B2 (en) Notch receptor agonists and uses
US7183388B2 (en) Anti-MUC-1 single chain antibodies for tumor targeting
JP3859695B2 (ja) Ｃ―ｅｒｂＢ―２外部ドメイン：ＧＰ７５
CA2419270C (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
JP5328155B2 (ja) Ａｄａｍ−９モジュレータ
JP2660241B2 (ja) モノクロナール抗体
US20030086929A1 (en) Treatment of prostate cancer by inhibitors of ATP synthase
JPH09511141A (ja) 受容体Ｔｉｅを認識するモノクローナル抗体およびそれらの用途
US5879898A (en) Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors
PL219043B1 (pl) Kompozycja farmaceutyczna, kompozycja farmaceutyczna do zastosowania w leczeniu choroby, czynnik do zastosowania w sposobie diagnozowania, czynnik do zastosowania w sposobie oznaczania regresji, cytolityczne lub wydzielające cytokinę komórki T do zastosowania w sposobie leczenia, kwas nukleinowy, komórka gospodarza, polipeptyd, przeciwciało, produkt sprzęgania przeciwciała i zestaw do wykrywania ekspresji
US20090280556A1 (en) Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas, and Ovarian Cancers and Methods and Kits for Targeting the Antigen
CA2572451C (en) Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature
RS56140B1 (sr) Genski proizvodi koji su diferencijalno izraženi u tumorima i njihova primena
CA2340721A1 (en) Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor
JPH08506801A (ja) Ｃｄ４４エキソン６に対応するペプチド、そのペプチドに特異的な抗体、および、腫瘍診断にそれらの抗体を使用する方法
US20030077676A1 (en) Anti-MUC-1 single chain antibodies for tumor targeting
WO2000018783A9 (en) Mammaglobin, a secreted mammary-specific breast cancer protein
JP4365583B2 (ja) ノッチレセプターアゴニスト及び用途
CA1286238C (en) Anti-epiglycanin monoclonal antibodies
AU2004289821B2 (en) Adenocarcinoma specific antibody SAM-6, and uses thereof
WO2006068822A1 (en) Notch receptor agonists and uses
JP3268147B2 (ja) モノクローナル抗体
HK1011697A1 (en) Monoclonal antibody active against cd44v6
HK1011697B (en) Monoclonal antibody active against cd44v6

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20041227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050328

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070405

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20070510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081125

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090319